Join Arrowhead Pharmaceuticals for Part I of its Summer Series of R&D webinars, featuring Lawrence Korngut, MD (University of Calgary Cumming School of Medicine) and company management, who will discuss the following Targeted RNAi Molecule (TRiM^TM) platform-derived development programs:

• ARO-DM1, an RNAi conjugate designed to specifically silence DMPK mRNA in skeletal muscle, currently being evaluated in Phase 1/2a dose-escalating study in patients with type 1 myotonic dystrophy
• ARO-DUX4, an RNAi conjugate designed to specifically target the gene that encodes human double homeobox 4 (DUX4) protein, currently being evaluated in Phase 1/2a dose-escalating study in adult patients with facioscapulohumeral muscular dystrophy (FSHD)

A live question and answer will follow the formal presentations.